Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 5/20 | 0.71 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3471157 | 0.87 | THRB (0.70) | THRBCXCR3NPC1KDM4ESMN1; SMN2 | |
| SCHEMBL3472707 | 0.83 | THRB (1.00) | THRBNPC1SMN1; SMN2DRD2KLKB1 | |
| SCHEMBL3471171 | 0.78 | THRB (0.70) | THRBNPC1SMN1; SMN2DRD2MEN1 | |
| SCHEMBL3474170 | 0.77 | THRB (0.78) | THRBNPC1SMN1; SMN2HPGDDRD2 | |
| SCHEMBL3472086 | 0.75 | THRB (0.75) | THRBNPC1DRD2KLKB1MEN1 | |
| SCHEMBL3471611 | 0.74 | THRB (0.70) | THRBNPC1DRD2ALDH1A1 | |
| SCHEMBL3472393 | 0.73 | THRB (0.72) | THRBNPC1DRD2ALDH1A1ROCK2 | |
| SCHEMBL3471703 | 0.72 | THRB (1.00) | THRBNPC1KLKB1ALDH1A1ROCK2 | |
| SCHEMBL3471139 | 0.72 | THRB (0.59) | THRBCXCR3NPC1KDM4ESMN1; SMN2 | |
| SCHEMBL3928231 | 0.71 | THRB (0.68) | THRBNPC1DRD2KLKB1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105663-A1 | 2-(HETEROARYL) ALKYL INDAZOLE 6-PHENYL AND THIENYL METHYL AMIDE AS THROMBIN INHIBITORS | BAYER HEALTHCARE AG (DE) | 2010-04-29 | — | — | US | disclosed |
| US-20100105663-A1 | 2-(HETEROARYL) ALKYL INDAZOLE 6-PHENYL AND THIENYL METHYL AMIDE AS THROMBIN INHIBITORS | BAYER HEALTHCARE AG (DE) | 2010-04-29 | — | — | US | disclosed |
| US-20100105663-A1 | 2-(HETEROARYL) ALKYL INDAZOLE 6-PHENYL AND THIENYL METHYL AMIDE AS THROMBIN INHIBITORS | BAYER HEALTHCARE AG (DE) | 2010-04-29 | — | — | US | disclosed |
| EP-2044031-A1 | 2-(HETEROARYL) ALKYL INDAZOLE 6-PHENYL AND THIENYL METHYL AMIDE AS THROMBIN INHIBITORS | Bayer HealthCare AG (DE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008006479-A1 | 2-(HETEROARYL) ALKYL INDAZOLE 6-PHENYL AND THIENYL METHYL AMIDE AS THROMBIN INHIBITORS | BAYER HEALTHCARE AG (DE) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008006479-A1 | 2-(HETEROARYL) ALKYL INDAZOLE 6-PHENYL AND THIENYL METHYL AMIDE AS THROMBIN INHIBITORS | BAYER HEALTHCARE AG (DE) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105663-A1 | 2-(HETEROARYL) ALKYL INDAZOLE 6-PHENYL AND THIENYL METHYL AMIDE AS THROMBIN INHIBITORS | F2, TFPI, PLAT | THRB 548/4885CXCR3 2955/4885NPC1 2941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.